{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:15:00Z","timestamp":1788387300076,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s12149-019-01338-9","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T15:53:30Z","timestamp":1550678010000},"page":"280-287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prognostic role of \u0394MTV and \u0394TLG in Burkitt lymphoma"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0810-6494","authenticated-orcid":false,"given":"Domenico","family":"Albano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Giubbini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"1338_CR1","volume-title":"World Health Organization classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008."},{"key":"1338_CR2","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3109\/07357900009012197","volume":"18","author":"PC Bishop","year":"2000","unstructured":"Bishop PC, Rao VK, Wilson WH. Burkitt\u2019s lymphoma: molecular pathogenesis and treatment. Cancer Invest. 2000;18:574\u201383.","journal-title":"Cancer Invest"},{"key":"1338_CR3","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1182\/blood-2004-02-0405","volume":"104","author":"KA Blum","year":"2004","unstructured":"Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009\u201320.","journal-title":"Blood"},{"key":"1338_CR4","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/annonc\/mdt058","volume":"24","author":"T W\u00e4sterlid","year":"2013","unstructured":"W\u00e4sterlid T, Brown PN, Hagberg O, Hagberg H, Pedersen LM, D\u2019Amore F, et al. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol. 2013;24:1879\u201386.","journal-title":"Ann Oncol"},{"key":"1338_CR5","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","volume":"379","author":"EM Molineux","year":"2012","unstructured":"Molineux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, et al. Burkitt\u2019s lymphoma. Lancet. 2012;379:1234\u201344.","journal-title":"Lancet"},{"key":"1338_CR6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1365-2141.2012.09026.x","volume":"156","author":"JT Sandlund","year":"2012","unstructured":"Sandlund JT. Burkitt lymphoma: staging and response evaluation. Br J Hematol. 2012;156:761\u20135.","journal-title":"Br J Hematol"},{"key":"1338_CR7","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1089\/apc.2008.0174","volume":"22","author":"PA Just","year":"2008","unstructured":"Just PA, Fieschi C, Baillet G, Galicier L, Oksenhendler E, Moretti JL. 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in AIDS-related Burkitt lymphoma. AIDS Patient Care STDS. 2008;22:695\u2013700.","journal-title":"AIDS Patient Care STDS"},{"key":"1338_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/RLU.0b013e3181a34552","volume":"4","author":"W Zeng","year":"2009","unstructured":"Zeng W, Lechowicz MJ, Winton E, Cho SM, Galt JR, Halkar R. Spectrum of FDG PET\/CT findings in Burkitt lymphoma. Clin Nucl Med. 2009;4:355\u20138.","journal-title":"Clin Nucl Med"},{"key":"1338_CR9","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1016\/j.ejrad.2009.07.035","volume":"75","author":"D Karantanis","year":"2012","unstructured":"Karantanis D, Durski JM, Lowe VJ, Nathan MA, Mullan BP, Georgiou E, et al. 18F-FDG PET and PET\/CT in Burkitt\u2019s lymphoma. Eur J Radiol. 2012;75:e68\u201373.","journal-title":"Eur J Radiol"},{"key":"1338_CR10","first-page":"54","volume":"16","author":"C Bailly","year":"2014","unstructured":"Bailly C, Eug\u00e8ne T, Couec ML, Strullu M, Frampas E, Campion L, et al. Prognostic value and clinical impact of (18)FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy. Front Med (Lausanne). 2014;16:1:54.","journal-title":"Front Med (Lausanne)"},{"key":"1338_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/ejh.12284","volume":"94","author":"E Carrillo-Cruz","year":"2015","unstructured":"Carrillo-Cruz E,, Rodr\u0131guez MS, Borrego-Dorado I, de la Cruz Vicente F, Quiroga Cantero E, et al. Mar \u0131n-Oyaga (?) VA. Role of 18F-FDG-PET\/CT in the management of Burkitt lymphoma. Eur J Haematol. 2015;94:23\u201330.","journal-title":"Eur J Haematol"},{"issue":"34","key":"1338_CR12","first-page":"608","volume":"2","author":"WX Wei","year":"2015","unstructured":"Wei WX, Huang JJ, Li WY, Zhang X, Xia Y, Jiang WQ, et al. Prognostic values of interim and post-therapy 18F-FDG PET\/CT scanning in adult patients with Burkitt\u2019s lymphoma. Chin J Cancer. 2015;2(34):608\u201313.","journal-title":"Chin J Cancer"},{"key":"1338_CR13","first-page":"1","volume":"3","author":"D Albano","year":"2018","unstructured":"Albano D, Bosio G, Re A, Pagani C, Giubbini R, Bertagna F. Metabolic behaviour and prognostic value of early and end of treatment 18F-FDG PET\/CT in adult Burkitt lymphoma: role of Deauville and IHP criteria. Leuk Lymphoma. 2018;3:1\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1338_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00259-018-4173-2","volume":"46","author":"D Albano","year":"2019","unstructured":"Albano D, Bosio G, Pagani C, Re A, Tucci A, Giubbini R, et al. Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in Burkitt lymphoma. Eur J Nucl Med Mol Imaging. 2019;46:87\u201396.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1338_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1053\/j.semnuclmed.2017.09.005","volume":"48","author":"L Kostakoglu","year":"2018","unstructured":"Kostakoglu L, Chauvie S. Metabolic tumour volume metrics in lymphoma. Semin Nucl Med. 2018;48:50\u201366.","journal-title":"Semin Nucl Med"},{"key":"1338_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00277-012-1640-x","volume":"92","author":"DH Yang","year":"2013","unstructured":"Yang DH, Ahn JS, Byun BH, Min JJ, Kweon SS, Chae YS, et al. Interim PET\/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Ann Hematol. 2013;92:471\u20139.","journal-title":"Ann Hematol"},{"key":"1338_CR17","first-page":"1411","volume":"16","author":"LF O\u00f1ate-Oca\u00f1a","year":"2018","unstructured":"O\u00f1ate-Oca\u00f1a LF, Cort\u00e9s V, Castillo-Llanos R, Terrazas A, Garcia-Perez O, Pital\u00faa-Cortes Q, et al. Metabolic tumor volume changes assessed by interval 18fluorodeoxyglucose positron emission tomography-computed tomography for the prediction of complete response and survival in patients with diffuse large B-cell lymphoma. Oncol Lett. 2018;16:1411\u20138.","journal-title":"Oncol Lett"},{"key":"1338_CR18","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.1038\/bcj.2015.51","volume":"5","author":"E Malek","year":"2015","unstructured":"Malek E, Sendilnathan A, Yellu M, Petersen A, Fernandez-Ulloa M, Driscoll JJ. Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods. Blood Cancer J. 2015;5:e326.","journal-title":"Blood Cancer J"},{"key":"1338_CR19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12885-015-1193-1","volume":"15","author":"SH Jung","year":"2015","unstructured":"Jung SH, Ahn JS, Kim YK, Kweon SS, Min JJ, Bom HS, et al. Prognostic significance of interim PET\/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma. BMC Cancer. 2015;15:198.","journal-title":"BMC Cancer"},{"key":"1338_CR20","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"1338_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1338_CR22","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","volume":"36","author":"U D\u00fchrsen","year":"2018","unstructured":"D\u00fchrsen U, M\u00fcller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, et al. Positron emission tomography-guided therapy of aggressive non-hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36:2024\u201334.","journal-title":"J Clin Oncol"},{"key":"1338_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2563","author":"D Albano","year":"2018","unstructured":"Albano D, Bosio G, Camoni L, Farina M, Re A, Tucci A, et al. Prognostic role of baseline 18F-FDG PET\/CT parameters in MALT lymphoma. Hematol Oncol. 2018. \n                    https:\/\/doi.org\/10.1002\/hon.2563\n                    \n                  .","journal-title":"Hematol Oncol."},{"key":"1338_CR24","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","volume":"130","author":"AJ Moskowitz","year":"2017","unstructured":"Moskowitz AJ, Schoder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017;130:2196\u2013203.","journal-title":"Blood"},{"key":"1338_CR25","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","volume":"41","author":"M Sasanelli","year":"2014","unstructured":"Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A, et al. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:2017\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1338_CR26","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","volume":"43","author":"NG Mikhaeel","year":"2016","unstructured":"Mikhaeel NG, Smith D, Dunn JT, Phillips M, M\u00f8ller H, Fields PA, et al. Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43:1209\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1338_CR27","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s12149-018-1274-8","volume":"32","author":"D Albano","year":"2018","unstructured":"Albano D, Bertoli M, Battistotti M, Rodella C, Statuto M, Giubbini R, et al. Prognostic role of pretreatment 18F-FDG PET\/CT in primary brain lymphoma. Ann Nucl Med. 2018;32:532\u201341.","journal-title":"Ann Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-019-01338-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-019-01338-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-019-01338-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T19:22:10Z","timestamp":1582140130000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-019-01338-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1338"],"URL":"https:\/\/doi.org\/10.1007\/s12149-019-01338-9","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,20]]},"assertion":[{"value":"13 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participant included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}